Clorox Q2 Earnings Rise 53% to $332M, Revenue Up 4.5% to $1.988B

Clorox Co. reported Q2 income of $332 million, up from $216 million last year. Earnings per share (EPS) increased to $2.68, compared to $1.73 last year. Revenue rose 4.5% to $1.988 billion. The company has provided full-year EPS guidance of $5.95 to $6.30.

Clorox Co. (CLX) reported its quarterly earnings for the second quarter of 2025, with net income increasing to $332 million, up from $216 million in the same period last year. The company's earnings per share (EPS) rose to $2.68, compared to $1.73 in the previous year. Revenue for the quarter climbed 4.5% to $1.988 billion. Additionally, Clorox provided full-year EPS guidance for 2026, forecasting adjusted EPS between $5.95 and $6.30, which falls short of the estimated $6.44 [1].

The company's organic sales rose by 8%, topping the estimate of a 5.1% increase. Gross margin improved to 46.5%, higher than the estimated 44.2%. However, net sales decreased by 6% to 10%, and organic sales dropped by 5% to 9% for 2026. This decline is partially attributed to retailers reducing orders in anticipation of Clorox's ERP system transition in the US, which is expected to lower fiscal 2026 EPS by about 85 to 95 cents [1].

In the fourth quarter of 2025, Clorox reported adjusted EPS of $2.87, surpassing the estimate of $2.18. Net sales hit $1.99 billion, marking a 4.5% increase year-over-year and exceeding the estimated $1.93 billion. Household net sales grew 7% year-over-year to $639 million, outperforming the $611.7 million estimate. Lifestyle net sales saw a 3.4% increase year-over-year, totaling $339 million, slightly below the $344.4 million estimate. Health and wellness net sales surged 14% year-over-year to $741 million, beating the $691.8 million estimate. International net sales decreased by 0.7% year-over-year to $269 million, missing the $273.5 million estimate [2].

The company's stock has lost about 22.3% since the beginning of the year, compared to the S&P 500's gain of 8.2%. Clorox shares are currently ranked as a Zacks Rank #5 (Strong Sell), indicating that the stock is expected to underperform the market in the near future [2].

References:
[1] https://www.smartkarma.com/home/newswire/earnings-alerts/clorox-company-clx-earnings-2026-eps-forecast-below-estimates-amid-sales-decline/
[2] https://www.nasdaq.com/articles/clorox-clx-q4-earnings-and-revenues-top-estimates